Abstract:

Objective   To investigate the clinical effects and adverse effects of weekly RHES as an hypoxic tumor cell radiosensitizer combined with radiotherapy in the treatment of nonsmall-cell lung cancer. Methods   50 hypoxia-positive cases of pathologically-diagnosed NSCLC (stage Ⅰ-Ⅲ) were randomly divided into the RHES + radiotherapy group (25 cases) and only radiotherapy group (25 cases). Intensity-modulated radiation therapy (IMRT)with a total dose of 60Gy/30F/6W was given to the 2 groups. The target area included primary foci and metastatic lymph nodes. In the RHES+radiotherapy group, RHES (15mg/d) was intravenously given during the first week. The therapeutic effects and adverse reactions were evaluated after treatment. Results   In RHES + radiotherapy and only radiotherapy groups, the total effective rate (CR+PR) was 80.0% and 44.0% (χ2=6.87，P＜0.01)，the one-year and two-yearlocal control rates were (78.9±8.4)% and (68.1±7.8)% (P＜0.05), (63.6±7.2)% and (43.4±5.7)% (P＜0.01)，the median survival time was (21.1±0.97) and (16.5±0.95) months (P＜0.01)，the one-year overall survival rate was (83.3±7.2)% and (76.6±9.3)% (P＞0.05), and the two-year overall survival rate was (46.3±2.4)% and (37.6±9.1)% (P＞0.05), respectively. Conclusion   RHES combined with radiotherapy within the first week has better short-term therapeutic effects and local control rate, and has no severe adverse reactions in treatment of NSCLC, but fails to significantly improve the one-year and two-year overall survival rates.

Key words: Recombinant human endostatin; Hypoxia; Carcinoma, non-small-cell lung; Radiotherapy